BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Executive Summary

• BioVaxys is providing a bi-weekly update regarding a Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission (BCSC) on March 3, 2026.
• The company has failed to file its audited annual financial statements and related certifications for the fiscal year ended October 31, 2025.
• Management anticipates completing the overdue annual filings by April 28, 2026, which will subsequently delay the filing of interim financial statements.

Key Details

• Missing Annual Filings: Audited annual financial statements for the year ended October 31, 2025, management’s discussion and analysis (MD&A), and Form 52-109FV1 CEO and CFO certifications (originally due February 28, 2026).
• Expected Completion Date: April 28, 2026.
• Auditor: Dale Matheson Carr-Hilton LaBonte LLP.
• Impact on Interim Filings: The company anticipates it will miss the April 1, 2026, deadline for interim financial statements and MD&A for the three months ended January 31, 2025; these will be filed immediately following the annual filings.
• MCTO Restrictions:
  • Prohibits the CEO and CFO from trading securities of the Company.
  • Prohibits the Company from directly or indirectly issuing or acquiring securities from insiders or employees until filings are complete and the MCTO is revoked.
• Public Trading Status: The general investing public can continue to trade the company's listed common shares freely.
• Compliance Status: The company confirms it is not subject to any insolvency proceedings and is adhering to alternative information guidelines under NP 12-203 by issuing bi-weekly status reports.